PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16259441-1	2004	The efficacy of the administration of famotidine, 20 mg BID, at early stages of gastroduodenal reflux disease (GDRD) based on a clinical and endoscopy study and treatment of patients of 0 and 1 degrees on the modified Savary-Miller scale.	Famotidine	38-48	BH3 interacting domain death agonist	Homo sapiens	56-59	
27536450-11	2014	CONCLUSION: The data indicate that overall more time is spent above the acidic threshold pH values when 80 mg/day of famotidine is administered TID vs BID.	Famotidine	117-127	BH3 interacting domain death agonist	Homo sapiens	151-154	
8750406-10	1995	For maintenance treatment of GERD, famotidine 20 mg BID and 40 mg BID are more effective than placebo in extending the time in remission.	Famotidine	35-45	BH3 interacting domain death agonist	Homo sapiens	52-55	
1746996-5	1991	In the group given famotidine 20 mg BID, there was a significantly greater proportion of patients with complete relief of daytime heartburn, and both famotidine groups demonstrated statistically significant advantages over placebo in global scores or by successful outcome.	Famotidine	19-29	BH3 interacting domain death agonist	Homo sapiens	36-39	
1746996-6	1991	Antacid consumption was significantly reduced in the group given famotidine 20 mg BID as compared with placebo.	Famotidine	65-75	BH3 interacting domain death agonist	Homo sapiens	82-85	
2342670-2	1990	In the severe oesophagitis group famotidine 40 mg bid, 13/29 (44%) healed at eight weeks and 17/29 (58%) at sixteen weeks.	Famotidine	33-43	BH3 interacting domain death agonist	Homo sapiens	50-53	
32180811-7	2020	The swelling subsided after administration of methylprednisolone 125 mg, epinephrine 1 mg/mL, injection 0.3 mL, diphenhydramine 25 mg, and famotidine 20 mg BID within 48 hours.	Famotidine	139-149	BH3 interacting domain death agonist	Homo sapiens	156-159